Results 231 to 240 of about 121,324 (293)

Seroprevalent study of cytomegalovirus infection in the regions of Jharkhand. [PDF]

J Family Med Prim Care
Sundi A, Roopa N, Gupta P, Irfan S, Kar TK.   +4 more
europepmc   +1 more source

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In total 169 patients already exposed to a JAKi and who received a second JAKi were retrospectively studied across 28 GETAID centres, with 48% reaching steroids‐free clinical remission after induction. Adverse events led to treatment discontinuation in 5% of cases.
Mathilde Osty, Romain Altwegg, Mélanie Serrero, Alban Benezech, Albane Lecomte, Guillaume Cadiot, Lucine Vuitton, Anne Wampach, Stéphane Nancey, Anthony Buisson, Catherine le Berre, Clea Rouillon, Cyrielle Gilletta, Felix Goutorbe, Mathurin Fumery, Nassim Hammoudi, Ludovic Caillo, Mathias Vidon, Nadia Arab, Gaelle Sickersen, Maryan Cavicchi, Sophie Vieujean, Maeva Charkaoui, Nicolas Richard, Pauline Wils, Bénédicte Caron, Aurélien Amiot, Alexandre Nuzzo, David Laharie, Julien Kirchgesner, Mathieu Uzzan, GETAID‐J2J group, Mathieu Uzzan, Adil Soualy, Mélanie Serrero, Lucas Guillo, Stéphane Nancey, Claire Gay, Gilles Boschetti, Catherine le Berre, Arnaud Boureille, Mathurin Fumery, Clara Yzet, Matthieu Allez, Nassim Hammoudi, Jean Marc Gornet, Pauline Wils, Maria Nachury, Aurélien Amiot, Antoine Meyer, Franck Carbonnel, Alexandre Nuzzo, Clément Bresteau, Thomas Bazin, David Laharie, Pauline Rivière, Florian Poullenot   +56 more
wiley   +1 more source

Enhancing the Predictions of Cytomegalovirus Infection in Severe Ulcerative Colitis Using a Deep Learning Ensemble Model: Development and Validation Study.

JMIR Med Inform
Kim JH, Choe AR, Byeon JR, Park Y, Song EM, Kim SE, Jeong ES, Lee R, Kim JS, Ahn SH, Jung SA.   +10 more
europepmc   +1 more source

Agreement Between Dried Blood Spot and Plasma PCR in Infants With Congenital Cytomegalovirus Infection. [PDF]

J Med Virol
Shimamura M, Kim J, Medoro AK, Flint K, Kaptsan I, Wang H, Pifer T, Harris R, Cuartas J, Leber A, Sánchez PJ.   +10 more
europepmc   +1 more source

Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium

British Journal of Haematology, EarlyView.
The overall survival of patients receiving an allogeneic haematopoietic stem cell transplant (HSCT) for GATA2 deficiency was significantly better if they were transplanted recently, with a bone marrow or cord blood graft and if the transplant was performed before the onset of excess blast. Excess blast before HSCT was the only factor associated with an
Flore Sicre de Fontbrune, Florian Chevillon, Mony Fahd, Kristell Desseaux, Xavier Poiré, Edouard Forcade, Arthur Sterin, Bénédicte Neven, Virginie Gandemer, Sylvain Thepot, Alice Garnier, Bruno Lioure, Ambroise Marcais, Stephanie Nguyen‐Quoc, Suzanne Tavitian, Laure Vincent, Jean Donadieu, Matthieu Resche Riggon, Sylvie Chevret, Marlene Pasquet, Regis Peffault de Latour   +20 more
wiley   +1 more source

Evidence for a Causal Association Between Human Cytomegalovirus Infection and Chronic Back Pain: A One-Sample Mendelian Randomization Study. [PDF]

JOR Spine
Naeini MK, Freidin MB, Smith IG, Ward S, Williams FMK.   +4 more
europepmc   +1 more source

Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)

British Journal of Haematology, EarlyView.
We report the UK experience of autologous haematopoietic stem cell transplantation (AHSCT) for multiple sclerosis (MS) in 364 patients. In our observational study, transplant‐related mortality was 1.4%, Epstein–Barr virus reactivation occurred in 75.9%, while disability progression‐free survival was 83.5% at 2 years post‐AHSCT and 62.4% at 5 years.
Majid Kazmi, Paolo A. Muraro, Varun Mehra, Ian Gabriel, Eleonora De Matteis, Gavin Brittain, Alice Mariottini, Richard Nicholas, Eli Silber, Julia Lee, Rachel Pearce, Ruth Paul, Maria Pia Sormani, Alessio Signori, Victoria Potter, Eduardo Olavarria, Ram Malladi, Basil Sharrack, John A. Snowden   +18 more
wiley   +1 more source

Anti-PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT-like and VITT-like characteristics. [PDF]

Br J Haematol
Nicolson PLR, Montague SJ, Buka RJ, Calvert A, Sheppard JI, Zhang Y, Wang JJ, Sharman J, Hassan E, Harrison J, Lawrence E, El-Dalil P, Parekh D, Osman H, Gordon TP, Nazy I, Warkentin TE, Lester WA.   +17 more
europepmc   +1 more source

Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase II multicentre FIL Copa‐BR trial from Fondazione Italiana Linfomi (FIL)

British Journal of Haematology, EarlyView.
A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, Luigi Marcheselli, Samantha Deianira Dattoli, Margherita Vannucchi, Delia Rota‐Scalabrini, Alessandra Tucci, Guido Gini, Giuseppe Tarantini, Donato Mannina, Annalisa Arcari, Arcangelo Liso, Elisabetta Scarpa, Dario Marino, Michele Spina, Ausilia Gorgone, Nicola Di Renzo, Salvatrice Mancuso, Luigi Petrucci, Agostino Tafuri, Barbara Botto, Francesca Bonello, Elisa Santambrogio, Umberto Vitolo   +24 more
wiley   +1 more source

Neonatal T cells unleash innate powers to combat congenital cytomegalovirus infection. [PDF]

J Clin Invest
Grassmann S.
europepmc   +1 more source